Increasing renal blood flow: Low-dose dopamine or medium-dose norepinephrine

David Di Giantomasso, Hiroshi Morimatsu, Clive N. May, Rinaldo Bellomo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background and objectives: Many clinicians believe that low-dose dopamine (LDD) [2 μg/kg/min] increases renal blood flow (RBF) and medium-dose norepinephrine (MD-NE) [0.4 μg/kg/min] decreases RBF. They also believe that MD-NE might induce mesenteric and/or coronary ischemia. In fact, the effects of these drugs on renal and vital organ blood flow are poorly understood. The aim of this study was to compare the effects of 6 h of IV LDD and MD-NE infusion on mammalian renal, coronary, mesenteric, and sagittal blood flow. Design: Randomized, controlled, experimental animal study. Setting: Animal laboratory of tertiary physiology institute. Subjects: Seven Merino cross sheep were studied. Measurements and results: We performed a staged insertion of transit-time flow probes around ascending aorta, sagittal sinus and circumflex coronary, superior mesenteric, and left renal arteries. We then randomized these animal with long-term embedded flow probes to either 6 h of placebo (saline solution) or drugs (MD-NE at 0.4 μg/kg/min or LDD at 2 μg/kg/min), and performed continuous measurement of systemic pressures, cardiac output (CO), and flow to vital organs. We also sampled blood and urine for the measurement of lactate, creatinine, and creatinine clearances at preset intervals. Results: Compared to placebo, LDD did not affect systemic hemodynamics. However, it increased mean RBF by 20% (267.3 ± 87.6 mL/min vs 222.0 ± 74.4 mL/min, p = 0.028) without a detectable effect on other vital regional circulations. MD-NE, however, increased mean arterial pressure (101.0 ± 8.3 mL/min vs 84.2 ± 5.2 mL/min, p = 0.018) [mean ± SD] and CO (4.93 ± 1.45 L/min vs 3.81 ± 0.57 L/min, p = 0.028). It also increased coronary blood flow (36.0 ± 15.7 mL/min vs 23.0 ± 10.7 mL/min, p = 0.018) and RBF (286.5 ± 79.0 mL/min vs 222.0 ± 74.4 mL/min, p = 0.018). MD-NE had no detectable effect on mesenteric or sagittal sinus flow. LDD infusion increased urine output, but did not change creatinine clearance. MD-NE infusion increased urine output significantly more than LDD but not creatinine clearance, Conclusions: Both LDD (2 μg/kg/min) and MD-NE (0.4 μg/kg/min) increased RBF and urine output. However, the effect of MD-NE was more pronounced. LDD did not affect other vital organ flows, but MD-NE increased coronary blood flow without any changes in mesenteric and sagittal sinus blood flow.

Original languageEnglish
Pages (from-to)2260-2267
Number of pages8
JournalChest
Volume125
Issue number6
DOIs
Publication statusPublished - Jun 2004
Externally publishedYes

Fingerprint

Renal Circulation
Dopamine
Norepinephrine
Creatinine
Urine
Cardiac Output
Placebos
Kidney
Coronary Sinus
Laboratory Animals
Renal Artery
Sodium Chloride
Pharmaceutical Preparations
Aorta
Lactic Acid
Sheep
Arterial Pressure
Ischemia
Hemodynamics
Pressure

Keywords

  • BP
  • Cardiac output
  • Coronary circulation
  • Creatinine clearance
  • Dopamine
  • Mesenteric circulation
  • Norepinephrine
  • Renal circulation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Increasing renal blood flow : Low-dose dopamine or medium-dose norepinephrine. / Di Giantomasso, David; Morimatsu, Hiroshi; May, Clive N.; Bellomo, Rinaldo.

In: Chest, Vol. 125, No. 6, 06.2004, p. 2260-2267.

Research output: Contribution to journalArticle

Di Giantomasso, David ; Morimatsu, Hiroshi ; May, Clive N. ; Bellomo, Rinaldo. / Increasing renal blood flow : Low-dose dopamine or medium-dose norepinephrine. In: Chest. 2004 ; Vol. 125, No. 6. pp. 2260-2267.
@article{850387420a8d4adda533758a3c043cc9,
title = "Increasing renal blood flow: Low-dose dopamine or medium-dose norepinephrine",
abstract = "Background and objectives: Many clinicians believe that low-dose dopamine (LDD) [2 μg/kg/min] increases renal blood flow (RBF) and medium-dose norepinephrine (MD-NE) [0.4 μg/kg/min] decreases RBF. They also believe that MD-NE might induce mesenteric and/or coronary ischemia. In fact, the effects of these drugs on renal and vital organ blood flow are poorly understood. The aim of this study was to compare the effects of 6 h of IV LDD and MD-NE infusion on mammalian renal, coronary, mesenteric, and sagittal blood flow. Design: Randomized, controlled, experimental animal study. Setting: Animal laboratory of tertiary physiology institute. Subjects: Seven Merino cross sheep were studied. Measurements and results: We performed a staged insertion of transit-time flow probes around ascending aorta, sagittal sinus and circumflex coronary, superior mesenteric, and left renal arteries. We then randomized these animal with long-term embedded flow probes to either 6 h of placebo (saline solution) or drugs (MD-NE at 0.4 μg/kg/min or LDD at 2 μg/kg/min), and performed continuous measurement of systemic pressures, cardiac output (CO), and flow to vital organs. We also sampled blood and urine for the measurement of lactate, creatinine, and creatinine clearances at preset intervals. Results: Compared to placebo, LDD did not affect systemic hemodynamics. However, it increased mean RBF by 20{\%} (267.3 ± 87.6 mL/min vs 222.0 ± 74.4 mL/min, p = 0.028) without a detectable effect on other vital regional circulations. MD-NE, however, increased mean arterial pressure (101.0 ± 8.3 mL/min vs 84.2 ± 5.2 mL/min, p = 0.018) [mean ± SD] and CO (4.93 ± 1.45 L/min vs 3.81 ± 0.57 L/min, p = 0.028). It also increased coronary blood flow (36.0 ± 15.7 mL/min vs 23.0 ± 10.7 mL/min, p = 0.018) and RBF (286.5 ± 79.0 mL/min vs 222.0 ± 74.4 mL/min, p = 0.018). MD-NE had no detectable effect on mesenteric or sagittal sinus flow. LDD infusion increased urine output, but did not change creatinine clearance. MD-NE infusion increased urine output significantly more than LDD but not creatinine clearance, Conclusions: Both LDD (2 μg/kg/min) and MD-NE (0.4 μg/kg/min) increased RBF and urine output. However, the effect of MD-NE was more pronounced. LDD did not affect other vital organ flows, but MD-NE increased coronary blood flow without any changes in mesenteric and sagittal sinus blood flow.",
keywords = "BP, Cardiac output, Coronary circulation, Creatinine clearance, Dopamine, Mesenteric circulation, Norepinephrine, Renal circulation",
author = "{Di Giantomasso}, David and Hiroshi Morimatsu and May, {Clive N.} and Rinaldo Bellomo",
year = "2004",
month = "6",
doi = "10.1378/chest.125.6.2260",
language = "English",
volume = "125",
pages = "2260--2267",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Increasing renal blood flow

T2 - Low-dose dopamine or medium-dose norepinephrine

AU - Di Giantomasso, David

AU - Morimatsu, Hiroshi

AU - May, Clive N.

AU - Bellomo, Rinaldo

PY - 2004/6

Y1 - 2004/6

N2 - Background and objectives: Many clinicians believe that low-dose dopamine (LDD) [2 μg/kg/min] increases renal blood flow (RBF) and medium-dose norepinephrine (MD-NE) [0.4 μg/kg/min] decreases RBF. They also believe that MD-NE might induce mesenteric and/or coronary ischemia. In fact, the effects of these drugs on renal and vital organ blood flow are poorly understood. The aim of this study was to compare the effects of 6 h of IV LDD and MD-NE infusion on mammalian renal, coronary, mesenteric, and sagittal blood flow. Design: Randomized, controlled, experimental animal study. Setting: Animal laboratory of tertiary physiology institute. Subjects: Seven Merino cross sheep were studied. Measurements and results: We performed a staged insertion of transit-time flow probes around ascending aorta, sagittal sinus and circumflex coronary, superior mesenteric, and left renal arteries. We then randomized these animal with long-term embedded flow probes to either 6 h of placebo (saline solution) or drugs (MD-NE at 0.4 μg/kg/min or LDD at 2 μg/kg/min), and performed continuous measurement of systemic pressures, cardiac output (CO), and flow to vital organs. We also sampled blood and urine for the measurement of lactate, creatinine, and creatinine clearances at preset intervals. Results: Compared to placebo, LDD did not affect systemic hemodynamics. However, it increased mean RBF by 20% (267.3 ± 87.6 mL/min vs 222.0 ± 74.4 mL/min, p = 0.028) without a detectable effect on other vital regional circulations. MD-NE, however, increased mean arterial pressure (101.0 ± 8.3 mL/min vs 84.2 ± 5.2 mL/min, p = 0.018) [mean ± SD] and CO (4.93 ± 1.45 L/min vs 3.81 ± 0.57 L/min, p = 0.028). It also increased coronary blood flow (36.0 ± 15.7 mL/min vs 23.0 ± 10.7 mL/min, p = 0.018) and RBF (286.5 ± 79.0 mL/min vs 222.0 ± 74.4 mL/min, p = 0.018). MD-NE had no detectable effect on mesenteric or sagittal sinus flow. LDD infusion increased urine output, but did not change creatinine clearance. MD-NE infusion increased urine output significantly more than LDD but not creatinine clearance, Conclusions: Both LDD (2 μg/kg/min) and MD-NE (0.4 μg/kg/min) increased RBF and urine output. However, the effect of MD-NE was more pronounced. LDD did not affect other vital organ flows, but MD-NE increased coronary blood flow without any changes in mesenteric and sagittal sinus blood flow.

AB - Background and objectives: Many clinicians believe that low-dose dopamine (LDD) [2 μg/kg/min] increases renal blood flow (RBF) and medium-dose norepinephrine (MD-NE) [0.4 μg/kg/min] decreases RBF. They also believe that MD-NE might induce mesenteric and/or coronary ischemia. In fact, the effects of these drugs on renal and vital organ blood flow are poorly understood. The aim of this study was to compare the effects of 6 h of IV LDD and MD-NE infusion on mammalian renal, coronary, mesenteric, and sagittal blood flow. Design: Randomized, controlled, experimental animal study. Setting: Animal laboratory of tertiary physiology institute. Subjects: Seven Merino cross sheep were studied. Measurements and results: We performed a staged insertion of transit-time flow probes around ascending aorta, sagittal sinus and circumflex coronary, superior mesenteric, and left renal arteries. We then randomized these animal with long-term embedded flow probes to either 6 h of placebo (saline solution) or drugs (MD-NE at 0.4 μg/kg/min or LDD at 2 μg/kg/min), and performed continuous measurement of systemic pressures, cardiac output (CO), and flow to vital organs. We also sampled blood and urine for the measurement of lactate, creatinine, and creatinine clearances at preset intervals. Results: Compared to placebo, LDD did not affect systemic hemodynamics. However, it increased mean RBF by 20% (267.3 ± 87.6 mL/min vs 222.0 ± 74.4 mL/min, p = 0.028) without a detectable effect on other vital regional circulations. MD-NE, however, increased mean arterial pressure (101.0 ± 8.3 mL/min vs 84.2 ± 5.2 mL/min, p = 0.018) [mean ± SD] and CO (4.93 ± 1.45 L/min vs 3.81 ± 0.57 L/min, p = 0.028). It also increased coronary blood flow (36.0 ± 15.7 mL/min vs 23.0 ± 10.7 mL/min, p = 0.018) and RBF (286.5 ± 79.0 mL/min vs 222.0 ± 74.4 mL/min, p = 0.018). MD-NE had no detectable effect on mesenteric or sagittal sinus flow. LDD infusion increased urine output, but did not change creatinine clearance. MD-NE infusion increased urine output significantly more than LDD but not creatinine clearance, Conclusions: Both LDD (2 μg/kg/min) and MD-NE (0.4 μg/kg/min) increased RBF and urine output. However, the effect of MD-NE was more pronounced. LDD did not affect other vital organ flows, but MD-NE increased coronary blood flow without any changes in mesenteric and sagittal sinus blood flow.

KW - BP

KW - Cardiac output

KW - Coronary circulation

KW - Creatinine clearance

KW - Dopamine

KW - Mesenteric circulation

KW - Norepinephrine

KW - Renal circulation

UR - http://www.scopus.com/inward/record.url?scp=2942736872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942736872&partnerID=8YFLogxK

U2 - 10.1378/chest.125.6.2260

DO - 10.1378/chest.125.6.2260

M3 - Article

C2 - 15189950

AN - SCOPUS:2942736872

VL - 125

SP - 2260

EP - 2267

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -